Article

Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS.

Dr. Panjwani Center for Molecular Medicine and Drug Research, University of Karachi, Karachi, Pakistan.
Biomarkers (Impact Factor: 1.88). 02/2012; 17(3):223-30. DOI: 10.3109/1354750X.2012.657245
Source: PubMed

ABSTRACT Smoking is the major contributor of lung cancer (LC), which accounts for millions of death.
This study focused on the correlation between the proteomic profiling of LC patients, and healthy nonsmokers and smokers.
Pattern-based peptide profiling of 186 plasma samples was performed through reversed-phase chromatography-18 magnetic bead fractionation coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis and resulted data were evaluated statistically by ClinProTool.
Marker peaks at m/z 1760, 5773, 5851, 2940, and 7172 were found with an excellent statistical figure.
Selected marker peaks can be served as a differentiated tool of LC patients with high sensitivity and specificity.

1 Bookmark
 · 
73 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent developments in mass spectrometry have introduced clinical proteomics to the forefront of diseases diagnosis, offering reliable, robust and efficient analytical method for biomarker discovery and monitoring. MALDI-TOF is a powerful tool for surveying proteins and peptides comprising the realm for clinical analysis. MALDI-TOF has the potential to revolutionize cancer diagnostics by facilitating biomarker discovery, enabling tissue imaging and quantifying biomarker levels. Healthy (control) and cancerous tissues can be analyzed on the basis of mass spectrometry (MALDI-TOF) imaging to identify cancer-specific changes that may prove to be clinically useful. We review MALDI-TOF profiling techniques as tools for detection of cancer biomarkers in various cancers. We mainly discuss recent advances including period from 2011 to 2013.
    Journal of pharmaceutical and biomedical analysis 03/2014; 95C:245-255. · 2.45 Impact Factor